Method for conservative management of plantar fasciitis

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and aims at conservative treatment of plantar fasciitis. That is ensured by administering platelet rich autoplasma in an amount of 2.0 ml for each injection into an attachment point of the plantar aponeurosis to the calcaneum (the heel sac), inner and outer side surfaces of a midfoot, as well as to a plantar surface of the midfoot. The autoplasma is prepared 1-2 hours before the procedure, and it contains from 1243 thousand/mcl to 3029 thousand/mcl platelets. The normal autoplasma contains from 162 thousand/mcl to 358 thousand/mcl platelets. The autoplasma is activated with 0.25% CaCl2 in a ratio of 2:1 with added 5% sodium hydrocarbonate in a ratio of 1:20 to the prepared platelet rich plasma.

EFFECT: above method enables providing pain management, recovering the extremity function, ensuring the stable clinical effect, and preventing complications.

2 ex

 

The invention relates to medicine, in particular of traumatology and orthopedics.

Known conservative treatment of plantar fasciitis with a decrease in physical activity; using orthopedic products, physiotherapy, cryotherapy, the use of ointments and gels; local administration of corticosteroids and nonsteroidal anti-inflammatory drugs (1. Belenky A.G. diseases of the periarticular tissues of the foot. CONSILIUM MEDICUM. - M., 2005; 7 (08/614); 2. Tsai WC, Wang CL, Tang FT, Hsu TC, Hsu KH, Wong MK. Treatment of proximal plantar fasciitis with ultrasound-guided steroid injection. Arch Phys Med Rehabil., 2000; 81(10):1416-21; 3. Chuckpaiwong B, Berkson EM, Theodore GH. Extracorporeal shock wave for chronic proximal plantar fasciitis: 225 patients with results and outcome predictors. - J. Foot. Ankle. Surg., 2009; 48(2):148-55; 4. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: a short-term, randomized, placebo-controlled, double-blind study. - Am. J. Med Rehabil., 2005;84(9):649-54. 5. Brook J, Dauphinee DM, Korpinen J, Rawe IM. Pulsed radio frequency electromagnetic field therapy: a potential novel treatment of plantar fasciitis. - J. Foot. Ankle. Surg., 2012; 51 (3):312-6).

When conservative therapy apply different methods of surgical treatment of a pathological focus (1. Allen BH, Fallat LM, Schwartz SM. Cryosurgery: an innovative technique for the treatment of plantar fasciitis. - J. Foot. Ankle. Surg., 2007; 46(2):75-94; 2. Hormozi J, Lee S, Hong DK. Minimal invasive percutaneous bipolar radio frequency for plantar fasciotomy: a retrospective study. - J. Foot. Ankle. Surg., 2011; 50(3):283-6. 3. Lane GD, London B. Heel spur syndrome: a retrospective report on the percutaneous transverse plantar incisional approach. - J. Foot. Ankle. Surg., 2004; 4(6):3 89-94).

Conservative methods of influence on the pathological focus have a positive effect in 72-83% of cases and are not long-lasting clinical effect. Surgical treatments can achieve a positive effect in 75-96% of cases, but the development of scar-adhesive processes in tissues can support reflex pathological process and to provoke exacerbation of pain. All of these methods of treatment of plantar fasciitis are only symptomatic and directed to relieving pain. These techniques do not resolve, and often aggravate degenerative-dystrophic changes in the plantar fascia and adjoining tissues. There is a clear need to find new more efficient pathogenetically reasonable method of treatment of this pathology.

The closest to the proposed method of treatment is a method of treating plantar fasciitis, wherein in the region of abnormal areas of the plantar aponeurosis (as determined by ultrasonography, once imposed platelet-rich plasma (BTP)obtained in the SmartPrep system (Barett S. Growth Factors for Chronic Plantar Fasciitis. - Podiatry Today, 2004, 17:36-42). We have adopted for the prototype.

However, this method has several disadvantages. Modern non-invasive methods for diagnosis of plantar is about fasciata not allow to identify the initial manifestations and prevalence of pathological process in the tissues. The introduction of BTP in small doses in point, detected by ultrasonography, may not resolve the pathologic lesion, because the process affects not only the plantar aponeurosis, and almost all the anatomical formation of the arch of the foot. Application for activation of platelets 10% calcium chloride causes burns membrane of platelets and the violation of their physiological activity (1. Shitikova A.S. Platelet hemostasis. - SPb., 2000; 2. Gibbon W and Long G: Ultrasound of the plantar aponeurosis (fascia). - Skeletal Radiology 28:21-26, 1999; 3. Chen WS, Wang TG, Lew HL. Can sonoelastography detect plantar fasciitis earlier than traditional B-mode ultrasonography? - Am. J. Phys. Med RehabiL, 2012; 91(2):185).

The objective of the invention is to increase the effectiveness of treatment of plantar fasciitis with the use of autologous growth factors and bioactive proteins to stimulate metabolism and processes of remodulate in pathologically altered tissue, reduce the frequency of side effects and the achievement of a stable clinical effect.

Conservative treatment of plantar fasciitis is that in the region of attachment of the plantar aponeurosis to the calcaneus (podpjatochnoj bag), inner and outer side surfaces of the middle Department, and the plantar surface of the middle division of the foot injected platelet-rich autoplasma in the amount of 2.0 ml for each injection, obtained 1-2 hours before the procedure and containing the th from 1243 thousand/ál to 3,029 thousand/µl platelets (normal - from 162 thousand/ál to 358 thousand/ál)pre-activated 0.25% solution of CaCl2in the ratio 2:1 with the addition of 5% sodium bicarbonate in a ratio of 1:20 to the received BTP. As follows from the prior art previously described, which allows to make a conclusion on the conformity of the proposal of the applicant to the criterion "novelty".

The method is as follows.

To obtain platelet-rich autoplasma (BTP) for 1-2 hours before manipulation to produce the blood from the cubital vein in special disposable plastic bags Gemany capacity 450 ml, containing 63 ml of anticoagulant on the basis of citrate. The blood is centrifuged at a rotary centrifuge PC for 6-7 minutes at 2500 rpm. Obtained in the supernatant plasma is subjected to a second centrifugation for 40 min at 2500 rpm. Then platelet-poor plasma is removed by extraction to 10-15 ml of platelet-rich autoplasma. Received RBC mass return in the bloodstream. Initial concentration of platelets in the blood of patients average of 274 thousand/µl and is in the range from 162 thousand/ál to 358 thousand/ál. The concentration of platelets in BTP averaged 1354 thousand/ml and ranged from 1243 thousand/ál to 3,029 thousand/ál. When evaluating indices of coagulation by standard techniques revealed that the coagulation time of plasma in the BTP in the eat declined by 2.6 times, in comparison with plasma, platelet-poor. Other indicators of coagulation was not changed. Received BTP mixed with 0.25% solution of CaCl2in the ratio 2:1 with the addition of 5% sodium bicarbonate in a ratio of 1:20 to the received BTP. After local anesthesia of the skin with a solution of 0.5% lidocaine was carried out by the introduction of BTP in the region of attachment of the plantar aponeurosis to the calcaneus (podpjatochnoj bag), inner and outer side surfaces of the middle division of the foot and the plantar surface of the middle Department, infiltrating all layers in the layers below the subcutaneous fat using a 1.0-2.0 ml BTP for each injection.

Clinical example 1.

Patient Gorbushina Lyudmila Aleksandrovna, 49 years. Map No. 3812. Turned on admission to the hospital 12.11.10, complaining of constant pain in the heel region of the left foot, increasing physical activity, decreasing in peace. Ill for the last three years. Gait is impaired, limping on the left leg. Palpation of the left heel region, a sharp pain, mild swelling. Working in a laboratory in the clinical diagnostic laboratory. He has been through several courses of treatment with analgesics, physical therapy and repeated introduction in the area of attachment of the plantar aponeurosis to the calcaneus of diprospan, treatment had a small effect (up to Nadel), complete disappearance of pain were noted. After the examination the patient was diagnosed with plantar fasciitis of the left foot. 12.11.10, extracted blood volume to 450.0 ml, after double centrifugation, according to the above method, the obtained 10.0 ml BTP.

2 hours after blood sampling in the area of attachment of the plantar aponeurosis to the calcaneus (podpjatochnoj bag), inner and outer side surfaces of the middle division of the left foot, the plantar surface of the middle Department, with the aforementioned method, introduced in 2.0 ml BTP activated 0.25% solution l2with the addition of 5% sodium bicarbonate. Complications during the procedure is not observed. Within 10 days after the treatment notes the decrease in pain. 26.11.10 was performed similar to the above described procedure. Examined after 3 weeks, the pain didn't bother. At objective inspection swelling no pain to palpation no notes. Discharged in a satisfactory condition. Examined after 6, 12 and 24 months, no complaints, works on the same work.

Clinical example 2.

The patient started Alexander, 57 years. Map No. 4186. Turned on admission to the hospital 25.01.11, complaining of constant pain in the heel areas of both feet, increasing physical activity, decreasing in peace. Ill use the e 7 years, last year it celebrates its deterioration. Gait is disturbed, by type of duck, walks relying on a cane. Palpation of the heel areas of a sharp pain, more on the left, moderate edema. Works as a site supervisor in road company. Passed courses of treatment with analgesics, physical therapy, treatment had a small effect, complete disappearance of pain was not. The patient diagnosed with plantar fasciitis on both sides. 25.01.11, extracted blood volume to 450.0 ml, after double centrifugation, according to the above method, the obtained 15.0 ml BTP. 1.5 hours after collection of blood in the region of attachment of the plantar aponeurosis to the calcaneus (podpjatochnoj bag), inner and outer side surfaces of the middle division of the left foot, the plantar surface of the middle division on both sides, with the aforementioned method, introduced in 2.0 ml BTP activated 0.25% solution of CaCl2with the addition of 5% sodium bicarbonate. Complications during the procedure is not observed. At 14 days after treatment, the pain diminished, walks without a cane, complete disappearance of pain not notes. 15.02.11 carried out similar to the above described procedure. Examined after 1 month, the pain didn't bother. At objective inspection swelling no pain to palpation no notes. Was discharged in good with the being. Examined after 6, 12 and 18 months, no complaints, conducts an active way of life.

A positive treatment effect explained by the fact that with the introduction of BTP in degenerative changes in the tissue of the plantar surface of the foot begins the process of inflammation due to migration of neutrophils and, therefore, macrophages in degenerative tissue. In turn, activated macrophages produce numerous growth factors, including growth factors, platelets, interleukin 1, a fibroblast growth factor. Start the process of angiogenesis and collagen synthesis. This process leads to early tissue repair that is the most significant parameter of healing, followed by epithelialization, and ultimately started the process of hyaline cartilage remodulate tissues. The advantage of BTP as the basis for cell - BTP autologica, aerogene and non-toxic, which creates the ideal basis for cell incubation. There is no risk of introducing the virus of hepatitis, HIV and other infections. The method is simple, does not require expensive equipment and specialized training of medical personnel and can be used in the treatment of plantar fasciitis.

The described method of conservative treatment of plantar fasciitis applied in 11 patients with unilateral and bilateral lesions of the feet. All patients were able to achieve copyrow is of pain syndrome from 7 to 24 months., restore full function of the leg and as a consequence full disability of the patient. Complications in the use of the proposed methodology was not.

Method of conservative treatment of plantar fasciitis by affecting the area of the abnormal areas of the plantar aponeurosis, characterized in that in the region of attachment of the plantar aponeurosis to the calcaneus (podpjatochnoj bag), inner and outer side surfaces of the middle Department, and the plantar surface of the middle division of the foot injected platelet-rich autoplasma in the amount of 2.0 ml for each injection, obtained 1-2 hours before the procedure and containing from 1243 thousand/ál to 3,029 thousand/µl platelets (normal - from 162 thousand/ál to 358 thousand/ál)pre-activated 0.25% solution of CaCl2in the ratio 2:1 with the addition of 5% sodium bicarbonate in a ratio of 1:20 to the received BTP.



 

Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions deals with medical prostheses for implantation into a human organism and methods of their manufacturing, in particular prosthesis of the jaw bone, which can be used in cosmetic surgery of the jaw bone or in the jaw bone reconstruction. Claimed is an implant of the jaw bone, manufactured in accordance with the method, including the following stages: selection of material of animal origin from an organism of cattle or pigs, with the material of animal origin being the jaw bone; shaping the material of animal origin to obtain a desirable shape of the jaw bone implant; removal of cells from the material of animal origin, crosslinking of the material of animal origin; removal of antigens from the material of animal origin; subjection of the material of animal origin to alkaline processing; introduction of active substances, improving adhesion on the implant of the growth factor and stem cells, produced by the human organism into the material of animal origin; packing the material of animal origin into a container with a sterilising solution. The jaw bone implant, manufactured by the said method, possesses high tissue compatibility.

EFFECT: group of inventions provides elimination of development or, at last, minimisation of phenomena of various types of discomfort under an impact of moving muscles in the period of the implant growing into tissues of the host organism, resorption and replacement with the new bone tissue with simultaneous provision of high tissue compatibility with elimination, or, at least, minimisation of phenomena of immunological rejection of a biological prosthesis of the jaw bone.

14 cl, 1 ex, 4 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I) , where R1 and R2 have the following values: (i) R1 and R2 together form =O; (ii) R1 and R2 together with carbon atom, which they are bound with, form duoxacycloalkyl; R1 represents hydrogen or halogen; and R2 represents halogen; (iv) R1 represents C1-6alkyl, where alkyl is optionally substituted with cyano, -RxS(O)qRv or -RxNRyRz; and R2 represents hydrogen; (v) R1 represents -OR12 or -NR13R14; and R2 represents hydrogen, deutero or phenyl, which is optionally substituted with halogen; R3 represents hydrogen, halogen, C1-6alkyl, cyano, halogen C1-6alkyl, C3-10cycloalkyl or C1-6alkoxy; R4 and R5 represent hydrogen; R6 is independently selected from halogen, C1-6alkyl, halogenC1-6alkyl, -RxOR18 and -RxS(O)qRv; R7 independently represents halogen or -RxORw; R12 is selected from hydrogen and C1-6alkyl, R13 represents hydrogen; R14 is selected from hydrogen, C3-10cycloalkyl, -C(O)Rv and -C(O)ORw; R18 represents hydrogen, C1-6alkyl, or pyperidinyl, where R18 is optionally substituted with 1-3 Q1 groups, each Q1 is independenly selected from hydroxyl, C1-6alkoxy, C1-6alkoxycarbonyl, carboxyl and morpholinyl; Rx independently represents C1-6alkylene or simple bond; Rv and Rw represent hydrogen or C1-6alkyl; Ry and Rz represent hydrogen; n has value 0-4; p has value 0-5; and each q independently has value 0, 1 or 2. Invention also relates to compounds of formula (II) , where substituents have values, given in the invention formula, to pharmaceutical composition, possessing inhibiting activity with respect to JAK kinases, containing compounds of formula (I) or (II), methods of treating JAK-modulated disease, and application of compounds of formula (I) or (II).

EFFECT: compounds of formula (I) or (II) as inhibitors of JAK kinases.

32 cl, 6 dwg, 2 tbl, 84 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to treating arthropathies, such as arthrosis and inflammatory loss of cartilage, tendon disorders and/or degenerative spine diseases. What is presented is a pharmaceutical composition for the above application, containing a corticosteroid and a cytokine antagonist - a natural or recombinant protein of interleukin IL-1Ra antagonist, particularly orthokine or anakinra, and optionally a growth factor; the composition is injectable into an injured nerve root, or into an injured intervertebral disk, or into their local context, or for intraarticular injection. There are presented: a kit comprising the pharmaceutical composition with the above cytokine antagonist and optionally the growth factor, and the pharmaceutical composition with the corticosteroid; using the above cytokine antagonist and optionally the growth factor for preparing the pharmaceutical composition to be used in combination therapy together with the corticosteroid for the above application; using the corticosteroid for preparing the pharmaceutical composition to be used in combination therapy with the above cytokine antagonist and optionally the growth factor for treating the above arthropathies, tendon disorders and/or degenerative spine diseases.

EFFECT: clinical success of treatment manifested by apparent joint detumescence, pain reduction by 60-100%, functional improvement of the joint, with the effect persisting 8 months later and more after the treatment.

39 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: composition for treating and preventing osteoarthritis and osteoarthrosis contains a powder or an extract of a dry plant specified in a group: burdock, dandelion, cowberry, birch, St.-John's wort, golden-rod, nettle, peppermint, licorice, cinquefoil, tormentil, brier, Greek valerian, valerian, corn, holy thistle, oat, agrimony, everlasting flower, ginseng, sage, starwort, squash, willow, wild strawberry, chicory, wheat-grass, Jerusalem artichoke, bilberry, marigold, horse radish, garlic, aspen, knotgrass, plantain, inula, Fagopyrum rubricaulis, chamomile flowers, balm lemon, blue poppy, cudweed, tripartite bur-marigold; a male larval bee lyophilisate and a quercetine or dihydroquercetine, or rutin powder in certain proportions.

EFFECT: composition is effective for treating and preventing osteoarthritis and osteoarthrosis, maintains the nutrition of the osteoarticular apparatus, growth and regeneration of connective tissue with no side effects, as well as enabled collagen synthesis for the recovery of connective and cartilage tissue, with preserving the anti-inflammatory and analgesic effect.

2 ex

FIELD: medicine.

SUBSTANCE: agent is prepared by boiling milled raw hard wheat grain in water, filtering, adding goat milk to the prepared brew, boiling, adding olive and sea buckthorn oil to prepare an oil mixture; further boiling milled herbal raw material in water, including chamomile blossom, elevated part of wormwood, elevated part of St. John's wort, rose hips, elevated part of mint, filtering, mixing the brew with the oil mixture to a homogenous state.

EFFECT: agent possesses high therapeutic activity in treating and preventing the locomotor diseases.

7 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and biotechnology, and may be used for the biocompatible polymeric structure formation in bone tissues. That is provided by a puncture approach to a filled cavity in the bone tissues. That is followed by filling the cavity with a polymeric gel compound containing 55-97.7 wt % of the biocompatible polymer polylactide of a particle size of 50 to 100 mcm, 0.3-45 wt % of magnetic nanoparticles of ferric oxide of a particle size of 10 to 100 nm, the gelling agent maltodexrin in the amount of 0.5 to 50 wt % of the weight of mixed polymer and magnetic nanoparticles, as well as distilled water in the amount of 0.5 to 100 wt % of the weight of a dry mixture of the polymer, magnetic nanoparticles and gelling agent. A solid three-dimension structure is formed. That is accompanied with heating the compound throughout by exposing to an alternating magnetic field at frequency 500 kHz and amplitude 500 E for 3-5 minutes. Where appropriate slow down the process of heating the compound, it is additionally exposed to a direct magnetic field at amplitude 1000 E applied either to the whole formed volume, or locally depending on the problem to be solved.

EFFECT: method enables forming the biocompatible three-dimension structure in the specified cavity of the bone tissue with minimum surgical intervention.

1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and pharmacology. The invention describes using ipidacrine for treating the locomotor diseases related to the solution of continuity. The above locomotor diseases are fractures, including delayed bone consolidation, delayed knitting, delayed fracture union, pathologic fracture, non-union fracture, and pseudoarthrosis. A pharmaceutical composition for treating the locomotor diseases contains ipidacrine as an active ingredient in an effective amount of 3 to 300 mg per a dose, and a pharmaceutically acceptable excipients. The composition is presented in the form of a tablet or a capsule.

EFFECT: invention extends the application of ipidacrine.

3 cl, 1 dwg, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to compounds, represented by formula (I) , where X1 and X2 independently represent CH or N; ring U represents benzene ring, pyrazole ring, 1,2,4-oxadiazole ring, 1,2,4-thiadiazole ring, isothiazole ring, oxazole ring, pyridine ring, thiazole ring or thiophene ring, m represents integer number, which has values from 0 to 1; n represents integer number, which has values from 0 to 3; R1 represents hydroxygroup or C1-6 alkyl; R2 represents any of (1)-(3): (1) halogen atom; (2) hydroxygroup; (3) C1-6 alkyl or C1-6 alkoxy, each of which can independently contain any group, selected from group of substituents α; group of substituents α includes fluorine atom and hydroxygroup, or its pharmaceutically acceptable salt. Invention also relates to pharmaceutical composition, possessing inhibiting activity with respect to xanthenes oxidase, including formula (I) compound or its pharmaceutically acceptable salt as active ingredient.

EFFECT: derivative, which contains condensed ring structure, intended as means for prevention and treatment of disease, associated with abnormal level of uric acid in serum.

15 cl, 11 tbl, 126 ex

FIELD: medicine.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for treating and preventing osteoarthritis and osteoarthrosis. The composition for treating and preventing osteoarthritis and osteoarthrosis contains a powder or an extract of a dry plant specified in a group: burdock, dandelion, cowberry, birch, St.-John's wort, golden-rod, nettle, peppermint, licorice, cinquefoil, tormentil, brier, Greek valerian, valerian, corn, holy thistle, oat, agrimony, everlasting flower, ginseng, sage, starwort, squash, willow, wild strawberry, chicory, wheat-grass, artichoke, bilberry, marigold, horse radish, garlic, aspen, knotgrass, plantain, inula, Fagopyrum rubricaulis, chamomile, balm lemon, blue poppy, cudweed, tripartite bur-marigold; a male larval bee lyophilisate and a quercetine or dihydroquercetine, or rutin powder in certain proportions.

EFFECT: composition is effective for treating and preventing osteoarthritis and osteoarthrosis, maintains the nutrition of the osteoarticular apparatus, the growth and regeneration of connective tissue with no side effects, as well as enabled collagen synthesis for the recovery of connective tissue, cartilage with preserving the anti-inflammatory and analgesic effect.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to traumatology and orthopedics, and can be used for prevention of purulent-inflammatory complications from application of apparatuses of external fixation in the process of treatment of patients in traumatology and orthopedics. For this purpose transosseous osteosynthesis of long tubular bones is performed by introduction of wires and intraosseous rods of compression-distraction apparatus of external fixation into their proximal and distal fragments. Antimicrobial substance is applied on the surface of wires and intraosseous rods before their introduction into proximal and distal fragments, as well as on degreased surface of patient's skin in places of entrance and exit of wires and intraosseous rods. As antimicrobial means used is gel-like nanostructured composite implant. It is replaced on degreased surface of skin in places of entrance and exit of wires and intraosseous rods 2-4 weeks after initial application. Composite implant includes platelet-enriched autoplasma, mixed in ratio 1:1.0-2.0 with granules of complex alloplastic preparation on the basis of hydroxyapatite, which contains 50-60 wt % of collagen. Said complex alloplastic preparation additionally contains 0.08-2.8 wt % of colloid solution of zerovalent metal silver Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, which is introduced into its granules at preparation stage. Size of introduced colloid zerovalent metal nanoparticles constitutes from 2 nm to 40 nm.

EFFECT: method ensures efficient prevention of purulent-inflammatory complications in such patients due to elimination of microbial risk of bacterial contaminations in treatment of patients by means of apparatuses of external fixation.

5 cl, 5 ex

FIELD: medicine.

SUBSTANCE: declared invention refers to veterinary science and aims at recovering the estrual cycling and fertility in cows suffering from hypo-ovarionism. The method involves single parenteral administration of the gonadotrophic preparation of a pregnant mare serum gonadotropin - folligon in a dose of 1,000 IU on the 7th day from the beginning of treatment with underlying pre-injections of 2.5% progesterone in a dose of 4 ml, on the 1st, 3rd and 5th days of the therapeutic course, 2% Sinestrol in a dose of 2 ml on the 1st and 3rd days, and Eleovit in a dose of 5 ml on the 1st and 7th day of treatment.

EFFECT: declared invention provides normalising the hormonal-metabolic status and the recovered functional ovarian activity in the cows.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for treating ulcerous pyloroduodenal stenosis. That is ensured by single injections of patient's platelet rich plasma into a gastric mucosa on the periphery of scar tissues of a pyloric canal all around uniformly into 6 points in a dose of 0.2 ml. Then the stenotic area is exposed to ionised argon plasma for 5-8 days in a mode of unipolar spray coagulation at a power of 30 W, an argon flow of 1.5 litres a minute for 5-6 seconds; the number of exposures per one session makes 3 to 5.

EFFECT: invention provides more effective non-invasive treatment of pyloroduodenal stenosis and reduces a length of treatment.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and aims at cell protection against the cytopathogenic action of hepatitis C virus. What is declared is a pharmaceutical composition possessing antiviral action on hepatitis C virus and a method for preparing it. The chicken broiler's head is electrically stimulated in a mode of 100-120 V 3-4 A for 3-4 s. The blood is sampled and incubated at 4-8°C for 18-24 hours. The serum is sampled. The sampled serum is filtered through a filter of a pore size of 10 nm, lyophilised and irradiated in a line electron accelerator (LEA) in a mode of 10-40 kGy.

EFFECT: using the declared group of inventions is effective for cell protection against the cytopathogenic action of hepatitis C virus.

2 cl, 2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, namely to a method of industrial production of fibrin-monomer from the blood plasma. The method of industrial production of fibrin-monomer from the blood plasma consists in defrosting fresh frozen human plasma with continuous mixing, with further addition into plasma of a saturated ammonium sulphate solution, the obtained mixture is kept at a temperature, after which it is centrifuged, a supernatant liquid is poured out; after that, urea is dissolved in a phosphate buffer and heated, with further dissolution in the buffer of the earlier obtained fibrinogen sediment, then, human thrombin is added and mixed; the mixture is kept at a room temperature, further, the obtained mixture is divided into three parts, the phosphate buffer is introduced into a reservoir with one of the three parts of the initial fibrinogen solution, a fibrin clot, formed in the reservoir is collected, washed in distilled water and pressed, as a result, three washed fibrin clots are obtained, after that, washing of the fibrin clot is repeated two more times in the same way, the final product - fibrin-monomer is obtained by dissolution of the washed fibrin clot in an acetate buffer with urea, the obtained fibrin-monomer is poured into flasks, after that, flasks with fibrin-monomer are frozen and freeze-dried under specified conditions.

EFFECT: method makes it possible to increase the output of fibrin-monomer.

2 ex

FIELD: medicine.

SUBSTANCE: what is applied is a stocking coating of an autogenous bone with a patient's platelet-rich plasma. Bone marrow aspirate from the patient's ilium and/or mesenchymal stromal cell autoculture prepared of the aspirate by culturing in vitro are injected under the coating layer into the autogenous bones. The autogenous bones are placed tightly in the bone defect to cover the defect area with adjacent soft tissues.

EFFECT: complete and effective synthesis of the bone tissue continuity by creating conditions of proliferative process isolation and osteoresorption process deceleration in the autogenous bone with no undesired immunological responses in the plasty area.

1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: with underlying conventional treatment, a leukocyte serum preparation is used that is produced by incubation of 20-30 ml of a patient's whole blood bottled in three sealed flasks in a thermostat at a temperature of 37-38°C for 24, 48 and 66-68 hours respectively; then the flasks are removed from the thermostat; the leukocyte serum is aspirated by a sterile syringe; the leukocyte serum preparation prepared at different times is introduced into the patient three times subcutaneously in a dose of 2-5 ml daily or triduan.

EFFECT: method provides higher clinical effectiveness and reduced length of treatment.

2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to medicine and specifically to trauma surgery and orthopaedics, and can be sued for surgical treatment of ununited fractures and false joints of cylindrical bones when there is a shortage of soft tissue. The method involves, 5-6 days before an operation, performing needle biopsy of bone and soft tissue fragments from the damage centre of the cylindrical bone and determining presence and nature of obligate intracellular viral infection (OIVI). Super-selective angiographic analysis of the microvascular channel to the capillary link is also performed. Valtrex is administered to the patient 2-4 days before the operation in a dose of 500 mg twice a day. Further, the method involves performing osteosynthesis or re-osteosynthesis with resection of the ends of bone fragments, opening marrowy canals, bone stimulation and batting the space of the bone defect with a gel-like nanostructured composite implant. In the presence of OIVI, resection of bone fragments is carried out in a larger volume until the onset of "pinpoint bleeding", i.e. to areas with satisfactory intrabone blood supply. The composite implant contains thrombocyte-rich autoplasma, mixed in ratio of 1:(1-2) with granules of a complex alloplastic preparation (CAP) based on hydroxyapatite which contains 50-60 wt % collagen. The composite implant also contains either 0.08-2.8 wt % colloidal solution of nanoparticles of zero-valent silver metal Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, or 5-12 wt % nanoparticles of said metals in dry form. The nanoparticles have size of 2-40 nm. A colloidal solution of said nanoparticles or colloidal nanoparticles of said metals in dry form is added to the CAP granules. Further, the prepared granules of the gel-like complex alloplastic preparation are laid in a selected ratio on the layer of thrombocyte-rich autoplasma, without mixing, for subsequent transfer into the bone defect space. In case of performing resection of bone fragments in a larger volume until the onset of "pinpoint bleeding", corticotomy is further performed on the cylindrical bone being operated on, with subsequent distraction of the bone regenerate using any existing method. Further, the bone fragments are repositioned, followed by metallo-osteosynthesis. Before wound suturing, the surface of the area with shortage of soft tissue in the projection of the ununited fracture and false joints is covered by a semi-permeable flexible plate made of the complex alloplastic preparation based on hydroxyapatite, which contains 50-60 wt % collagen. The plate has thickness of 0.25-1.2 mm. The surface area of the plate is 10-20% greater than the area with shortage of soft tissue in the corresponding projection. The part of the erythrocyte mass remaining from preparing the thrombocyte-rich autoplasma and the plasma are returned into the bloodstream of the patient by intravenously using a drip during the surgical procedure or in the early post-operation period. After the operation, valtrex is administered to the patient in a dose of 500 gm once a day for two weeks and then in a dose of 500 mg every other day for two weeks.

EFFECT: method provides reliable prevention of OIVI at a damage centre, normalisation of local microcirculation of blood, avoiding ischemic processes, and compensation for the shortening of the length of the limb of the patient being operated on while preventing weakening of the process of reparative osteogenesis and allergic reactions of the body.

6 cl, 4 ex

FIELD: medicine.

SUBSTANCE: common procedure is used to prepare platelet rich plasma to be administered at three stages. At the first stage, the platelet rich plasma is injected using an insulin syringe along a lateral surface of a penis in a bilateral direction: the autoplasma 1.0 ml is injected in a proximal, medial and distal direction; totally the autoplasma 3.0 ml is injected into each cavernous body. At the second stage, the autoplasma 2.0 ml is injected under an albugineous coat of the penis under ultrasonic control. The third stage involves injecting the autoplasma into sciatic-cavernous muscles 1.0 ml each with the penis slightly massaged to distribute the autoplasma. The procedure is repeated for three times every 1 week. The method enables stimulating the growth and development of the cavernous vessels promoting its revascularisation, improves the penis innervation, as well as enhances the functional capacities of the endothelium. The higher tone of the sciatic-cavernous muscles promotes better venous-occlusive component.

EFFECT: regular spontaneous sleeping erections, improved morning erections, higher quality of patient's sex life.

1 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for normalising (improving, recovering, stimulating) the mammalian, especially human, reproductive function. That involves the oral administration of a preparation representing high-lactate milk whey (HLMW) that contains 7% of dry substances, including 5% of milk whey and 2% of sodium hydroxide, or ammonium carbonate, or calcium hydroxide prepared by hydrolysis of milk whey pasteurised at temperature 53-57°C in the culture environment of Lactobacillus acidophilum and Lactobacillus bulgaricum at culture temperature 36 to 40°C and neutralisation of formed lactic acid with sodium hydroxide, or ammonium carbonate, or calcium hydroxide to achieve a weight fraction of lactose no more than 0.2%.

EFFECT: method enables normalising the reproductive function, as well as its usage provides increasing the specific and non-specific body resistance and improving the erythropoiesis.

4 cl, 7 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to traumatology and orthopedics, and can be used for prevention of purulent-inflammatory complications from application of apparatuses of external fixation in the process of treatment of patients in traumatology and orthopedics. For this purpose transosseous osteosynthesis of long tubular bones is performed by introduction of wires and intraosseous rods of compression-distraction apparatus of external fixation into their proximal and distal fragments. Antimicrobial substance is applied on the surface of wires and intraosseous rods before their introduction into proximal and distal fragments, as well as on degreased surface of patient's skin in places of entrance and exit of wires and intraosseous rods. As antimicrobial means used is gel-like nanostructured composite implant. It is replaced on degreased surface of skin in places of entrance and exit of wires and intraosseous rods 2-4 weeks after initial application. Composite implant includes platelet-enriched autoplasma, mixed in ratio 1:1.0-2.0 with granules of complex alloplastic preparation on the basis of hydroxyapatite, which contains 50-60 wt % of collagen. Said complex alloplastic preparation additionally contains 0.08-2.8 wt % of colloid solution of zerovalent metal silver Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, which is introduced into its granules at preparation stage. Size of introduced colloid zerovalent metal nanoparticles constitutes from 2 nm to 40 nm.

EFFECT: method ensures efficient prevention of purulent-inflammatory complications in such patients due to elimination of microbial risk of bacterial contaminations in treatment of patients by means of apparatuses of external fixation.

5 cl, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to surgery, and can be used in treating patients with pancreatonecrosis. For this purpose, opening the omental sac and performing the pancreatic gland abdomination along a lower edge of its body and tail are followed by puncturing retroperitoneal fat with introducing components No.1 and No.2 therein. First, component No.1 consisting of dry lyophilized cryoprecipitate 50-70 g dissolved in normal saline 100 ml is slowly administered. Then 10 minutes later, the retroperitoneal fat is additionally punctured, and component No.2 consisting of NIH sterile thrombin dissolved in 5% s-aminocapronic acid 10 ml is introduced. An artificial fibrin barrier is formed in the retroperitoneal fat 5-7 minutes later by mixing and polymerising the two solutions.

EFFECT: method provides the effective treatment of pancreatonecrosis by forming the artificial fibrin barrier on the way of a potential impregnation of the retroperitoneal fat in an enzymatic fluid.

3 dwg, 2 ex

Up!